The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD4+ T-cell count eligibility by HIV status among participants receiving immunotherapy for cancer diagnoses.
 
Thomas A Odeny
No Relationships to Disclose
 
Matthew Harry Rosenthal
No Relationships to Disclose
 
Kathryn Anne Lurain
Research Funding - Celgene (Inst); CTI BioPharma Corp (Inst); EMD Serono (Inst); Merck (Inst)
 
Julius Strauss
Research Funding - Bavarian Nordic (Inst); EMD Serono (Inst); ImmunityBio (Inst); PDS Biotechnology (Inst); Precigen (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on NIH pending patent (Inst)
 
Thomas S. Uldrick
Consulting or Advisory Role - Abbvie; Seagen
Research Funding - Celgene (Inst); Merck (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - As an employee of the U.S. Government, I have provisional patent application regarding methods for the treatment of Kaposi’s sarcoma and KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
 
Robert Yarchoan
Research Funding - Celgene (Inst); CTI BioPharma Corp (Inst); EMD Serono (Inst); Genentech (Inst); Janssen Research & Development (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent related to increase in immune surface markers by pomalidomide, lenalidomide and related drugs in patients with KSHV-associated diseases (Inst); Patent(s) on the treatment of HIV and hepatitis virus with an antiviral drug and a vaccine to prevent resistance (Inst); Patents on the treatment of Kaposi sarcoma with IL-12 (Inst); Various patents including patents on anti-HIV therapies and soluble IL-2 receptor; mostly expired. (Inst); Various patents on vasostatin, KSHV vIL-6, internalization of surface markers, calreticulin, and calreticulin fragments (Inst)
 
Ramya Ramaswami
Research Funding - Celgene (Inst); CTI BioPharma Corp (Inst); EMD Serono (Inst); Genentech (Inst); Merck Serono (Inst)